Core Viewpoint - The 22nd China International Health Expo highlighted the achievements of Zhejiang Shouxiangu Pharmaceutical Co., Ltd., recognized as a leading enterprise in the health industry, showcasing its innovations in the Ganoderma lucidum sector and its commitment to traditional Chinese medicine and technological advancement [2][5]. Group 1: Company Achievements - Shouxiangu has established the world's largest Ganoderma lucidum germplasm resource bank, preserving over 13,388 varieties since the 1990s [3]. - The company developed the first domestically approved Ganoderma lucidum variety "XianZhi No. 1" in 2001, breaking the reliance on imports from Japan and South Korea [3]. - Shouxiangu has built over 10,000 acres of organic medicinal herb cultivation bases, achieving various organic certifications from China, the EU, the US, Japan, and Canada [3]. Group 2: Technological Innovations - The company has independently developed the third-generation wall-breaking technology for Ganoderma lucidum spore powder, significantly enhancing the effective ingredient content by over 10 times and improving absorption rates by an average of 29 times compared to regular wall-breaking spore powder [3]. - Shouxiangu has been recognized with a gold medal at the 46th Geneva International Exhibition of Inventions for its technological breakthroughs [3]. Group 3: Standardization and Digital Transformation - Since 2006, Shouxiangu has undertaken the development of over 100 international, national, and industry standards, including ISO standards for Ganoderma lucidum and other medicinal herbs [4]. - The company is set to implement new ISO standards for "White Atractylodes" and "Wall-Breaking Ganoderma lucidum spore powder" in July 2024 and July 2025, respectively, enhancing China's international influence in traditional medicine [4]. - Shouxiangu is advancing digital transformation by creating a collaborative application system across the entire industry chain, including smart farms and factories, which has led to a 50%-80% increase in medicinal herb yield and a 35% improvement in effective ingredient stability [4]. Group 4: Product Offerings and Cultural Heritage - At the expo, Shouxiangu showcased its core product lines, including Ganoderma lucidum, Dendrobium, and saffron, covering traditional Chinese medicine products, health foods, and herbal daily necessities [5]. - The company also presented its national intangible cultural heritage techniques for traditional Chinese medicine processing, emphasizing its commitment to cultural preservation alongside technological innovation [5].

Core Points - The Guangdong Provincial Traditional Chinese Medicine Association officially released the "Management Norms for Fresh Medicine in Medical Institutions" group standard (T/GDACM 0159-2025) on August 20, marking a significant step towards the standardization and normalization of fresh medicine management in clinical applications [1][2] - The standard was developed by Shenzhen Baoan Traditional Chinese Medicine Hospital (Group) in collaboration with over ten institutions, including Qingyuan Traditional Chinese Medicine Hospital and Guangzhou University of Traditional Chinese Medicine [1] - Fresh medicine, a traditional form of medication in TCM, has unique advantages such as rapid efficacy and complete retention of active ingredients, making it irreplaceable in clinical diagnosis and treatment, especially in the Lingnan region [1] Industry Impact - The implementation of the standard will promote the standardized application of fresh medicine in medical institutions, enhancing the TCM service capabilities and providing a more diversified TCM treatment experience for citizens [2] - The standard will serve as an important basis for the standardization and internationalization of TCM, while also driving the integrated development of the entire fresh medicine industry chain, including planting, processing, and logistics [2] - Baoan Traditional Chinese Medicine Hospital (Group) aims to leverage the opportunity presented by the standard's release to deepen the application of fresh medicine in clinical diagnosis and actively explore high-quality research projects to promote the industrialization and scaling of fresh medicine [2]

Core Viewpoint - The article highlights the journey of Shouxiangu, a leading company in the Chinese medicinal mushroom industry, under the leadership of Li Mingyan, emphasizing the integration of technology, standards, and digitalization in traditional Chinese medicine for future growth [2][7]. Company Development - Li Mingyan, the founder of Shouxiangu, has transformed the company into the first publicly listed entity in the Chinese lingzhi and dendrobium industry, showcasing over 40 years of research and development [2][4]. - The company has established international standards for traditional Chinese medicine, specifically for lingzhi and dendrobium, which have been adopted in over ten countries, including Japan and Australia [3][4]. Technological Innovation - Shouxiangu has developed a proprietary "four lows and one high" supersonic low-temperature airflow breaking technology, which enhances the extraction of effective components from lingzhi spores [4]. - The company has successfully cultivated 13 valuable medicinal mushroom varieties, including "XianZhi No. 1" and "XianHua No. 2," which have high active ingredient content [4]. Marketing and Branding - Shouxiangu has adopted modern marketing strategies, including sponsoring the Zhejiang swimming team, to enhance brand visibility and appeal to younger demographics [5][6]. - The company is focusing on digital transformation and new retail strategies to adapt to market changes and improve production quality [6]. Future Directions - Li Mingyan has set a vision for Shouxiangu to become a global benchmark in the lingzhi industry by continuously enhancing technological innovation and industry empowerment [7]. - The company is working on a digital platform that integrates IoT, genetic technology, and digital twin concepts to optimize agricultural practices and enhance product quality [6].

Core Insights - The National Key Laboratory for Traditional Chinese Medicine Quality Research at the University of Macau was established in 2010, marking it as the first national key laboratory in the field of traditional Chinese medicine [1][2] - The laboratory focuses on the standardization, internationalization, and modernization of traditional Chinese medicine, aiming to enhance the recognition and development of traditional Chinese medicine globally [1] - Recent advancements include the integration of artificial intelligence (AI) in traditional Chinese medicine research, significantly reducing the time required for small molecule screening from ten years to mere seconds [1] Group 1 - The laboratory has developed six internationally recognized key technology platforms, including traditional Chinese medicine chemistry, quality analysis, biological activity quality supervision, safety quality certification, traditional Chinese medicine manufacturing, and quality evaluation [2] - The laboratory's director emphasizes the importance of high-quality scientific research and the transformation of results to contribute to human health and well-being [2]

Core Insights - The Chinese government is promoting the quality enhancement and high-quality development of traditional Chinese medicine (TCM) through innovation and reform [1][5] - Shenzhen is positioning itself as a leader in TCM innovation, leveraging AI technology to improve healthcare services and patient outcomes [2][3][4] Group 1: Government Initiatives - In March, the State Council issued guidelines to enhance TCM quality, emphasizing technological innovation and systemic reforms [1] - Shenzhen's municipal government is actively conducting research to improve TCM inheritance and innovation mechanisms [1] Group 2: AI Integration in TCM - Shenzhen hospitals are implementing AI technologies, such as DeepSeek, to assist in TCM diagnostics and personalized treatment plans [3] - The integration of AI has led to significant improvements in operational efficiency, with a fivefold increase in logistics efficiency and reduced patient processing times [3] Group 3: Standardization and Quality Control - The lack of standardized practices in TCM has been identified as a barrier to its global promotion, necessitating the establishment of quality control standards [5][6] - Shenzhen's TCM institutions are encouraged to lead in the standardization of internal preparations and quality assurance [6] Group 4: Collaborative Development - Experts suggest that cross-disciplinary collaboration, including partnerships with tourism and education sectors, can enhance TCM's market presence and cultural dissemination [4] - The Shenzhen TCM sector is urged to leverage its strengths to influence surrounding regions and countries, particularly in Southeast Asia [1]